Imperial College London
Alternate

Professor Francis Drobniewski

Faculty of Medicine, Department of Infectious Disease

Chair in Global Health and Tuberculosis
 
 
 
//

Contact

 

f.drobniewski

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Balabanova:2017:10.1136/thoraxjnl-2016-209841,
author = {Balabanova, Y and Fiebig, L and Ignatyeva, O and Riekstina, V and Danilovits, M and Jaama, K and Davidaviciene, E and Radiulyte, B and Popa, CM and Nikolayevskyy, V and Drobniewski, F},
doi = {10.1136/thoraxjnl-2016-209841},
journal = {Thorax},
pages = {850--852},
title = {Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule?},
url = {http://dx.doi.org/10.1136/thoraxjnl-2016-209841},
volume = {72},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - WHO recently recommended the use of a shorter multidrug-resistant TB (MDR-TB) regimen under programmatic conditions. We assessed eligibility for this regimen in a cohort of 737 adult patients with MDR-TB from Latvia, Lithuania, Estonia and Bucharest city recruited in 2007 and 2009. Only 4.2% of the patients were eligible for this regimen. Ethambutol (64%), pyrazinamide resistance (58%) and previous exposure to second-line TB drugs were major reasons for non-eligibility. High-level resistance to isoniazid is expected due to widespread prevalence of katG mutations. In Eastern Europe, the use of the shorter regimen might be an exception rather than a rule.
AU  - Balabanova,Y
AU  - Fiebig,L
AU  - Ignatyeva,O
AU  - Riekstina,V
AU  - Danilovits,M
AU  - Jaama,K
AU  - Davidaviciene,E
AU  - Radiulyte,B
AU  - Popa,CM
AU  - Nikolayevskyy,V
AU  - Drobniewski,F
DO  - 10.1136/thoraxjnl-2016-209841
EP  - 852
PY  - 2017///
SN  - 1468-3296
SP  - 850
TI  - Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule?
T2  - Thorax
UR  - http://dx.doi.org/10.1136/thoraxjnl-2016-209841
VL  - 72
ER  -
Download